174 related articles for article (PubMed ID: 38421520)
21. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P; Vasiliki N; Kotteas E; Stratigos AJ; Fattore D; Orlandi A; Mannino M; Di Pumpo M; Fida M; Starace M; Apalla Z; Romano MC; Riganti J; Segura S; Martinez AF; Fabbrocini G; Sibaud V; Peris K; On Behalf Of The Eadv Task Force Dermatology For Cancer Patients
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509319
[TBL] [Abstract][Full Text] [Related]
24. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
25. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Vastarella M; Fabbrocini G; Sibaud V
Drug Saf; 2020 May; 43(5):395-408. PubMed ID: 31981081
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
27. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.
Anoop TM; Joseph P R; Pn M; Kp P; Gopan G; Chacko S
Clin Breast Cancer; 2021 Aug; 21(4):e434-e447. PubMed ID: 33608219
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".
Allais BS; Fay CJ; Kim DY; Semenov YR; LeBoeuf NR
Immunol Rev; 2023 Sep; 318(1):22-36. PubMed ID: 37583051
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis.
Kraehenbuehl L; Schneider S; Pawlik L; Mangana J; Cheng P; Dummer R; Meier-Schiesser B
Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513847
[TBL] [Abstract][Full Text] [Related]
32. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
33. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
34. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2021; 1342():319-330. PubMed ID: 34972971
[TBL] [Abstract][Full Text] [Related]
35. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.
Suh Oh HJ; Flórez Menéndez Á; Sacristán Santos V; Fernández Ribeiro F; Vilanova-Trillo L; Constenla Figueiras M; Pereiro Ferreiros M
Drugs Context; 2020; 9():. PubMed ID: 32821263
[TBL] [Abstract][Full Text] [Related]
37. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.
Çelik U; Aydemir EH; Engin B; Oba MÇ; Yılmaz M; Meşe ŞG
J Oncol Pharm Pract; 2021 Dec; 27(8):1853-1860. PubMed ID: 33131448
[TBL] [Abstract][Full Text] [Related]
38. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review.
Brown AM; Masterson W; Lo J; Patel AB
Dermatitis; 2023; 34(3):201-208. PubMed ID: 34405836
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy and skin reactions.
Fabbrocini G; Cameli N; Romano MC; Mariano M; Panariello L; Bianca D; Monfrecola G
J Exp Clin Cancer Res; 2012 May; 31(1):50. PubMed ID: 22640460
[TBL] [Abstract][Full Text] [Related]
40. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
